Skip to main content
All lobbying filings

PFIZER INC.

Lobbying for PFIZER INC.

 Filing 3rd Quarter - Report
3rd Quarter (July 1 - Sep 30) 2025 · District of Columbia · House · Senate · $2,730,000.00 expenses · posted Oct 20, 2025

Official filing document

 Bills named in this filing 3
 Lobbying activity 3
Health Issues

Vaccine Policy, Coverage and Access HR 4317 - PMB Reform Act of 2025 Gavi Vaccines Alliance Issues HR 2214 - DRUG Act S 832 - EPIC Act of 2025 S 864 - HELP Copays ACT S 882 - Patients Before Middlemen Act Prescription Drug-Use-Related Software (PDURS): Digital Medicine Lyme Disease Issues Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients IRA Biosimilars Pause Fix, Biosimilar Legislation H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Orphan Drug Exemption, Pill Penalty, Biosimilar Pause Vaccine Coverage and Access Drug Pricing

Medicare/Medicaid

Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients PBM Reform S 1702 - Access to Prescription Digital Therapeutics Act of 2025 Digital Therapeutics

Trade (domestic/foreign)

International Supply Chain Global Access Most Favored Nation Policies Tariffs Non-Tariff Trade Barriers United States-Mexico-Canada Agreement (USMCA)

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem